Morbidity and Mortality in Sarcoidosis

Overview

Journal Curr Opin Pulm Med

Specialty Pulmonary Medicine

Date 2014 Jul 17

PMID 25029298

Citations 46

Authors

Alicia K Gerke

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Chronic sarcoidosis is a complex disease with numerous comorbid conditions and can be fatal in some cases. Recognizing causes of morbidity and mortality is important to effectively select treatments, manage symptoms and improve outcomes. The purpose of this review is to examine emerging knowledge on morbidity and mortality in sarcoidosis.

Recent Findings: Approximately 1-5% of patients with sarcoidosis die from complications of sarcoidosis. Recent population studies indicate that mortality may be increasing over the past decade. The reasons behind these trends are unclear, but could include increasing incidence, detection rates, severity of disease or age of the population. Morbidity of sarcoidosis is reflected by a trend of increased hospitalizations over recent years and increased use of healthcare resources. Morbidity can be caused by organ damage from granulomatous inflammation, treatment complications and psychosocial effects of the disease. Recent studies are focused on morbidity related to cardiopulmonary complications, bone health and ageing within the sarcoidosis population. Last, sarcoidosis is associated with autoimmune diseases, pulmonary embolism and malignancy; however, the underlying mechanisms linking diseases continue to be debated.

Summary: Morbidity in sarcoidosis is significant and multifactorial. Mortality is infrequent, but may be increasing over the years.

Citing Articles

Rheumatologic Perspectives on Sarcoidosis: Predicting Sarcoidosis-Associated Arthritis Through Comprehensive Clinical and Laboratory Assessment.

Ekin A, Misirci S, Sertkaya O, Coskun B, Yagiz B, Dalkilic E J Clin Med. 2025; 13(24.

PMID: 39768486 PMC: 11728293. DOI: 10.3390/jcm13247563.

Neuropsychiatric manifestations of sarcoidosis.

Tana C, Bernardinello N, Raffaelli B, Garcia-Azorin D, Waliszewska-Prosol M, Tana M Ann Med. 2024; 57(1):2445191.

PMID: 39723989 PMC: 11703453. DOI: 10.1080/07853890.2024.2445191.

Autoantibodies in sarcoidosis: Innocent bystander or promising biomarker for organ involvement?.

Pozzan R, Salton F, Confalonieri P, Trotta L, Barbieri M, Reccardini N Sarcoidosis Vasc Diffuse Lung Dis. 2024; 41(4):e2024056.

PMID: 39655585 PMC: 11708945. DOI: 10.36141/svdld.v41i4.16043.

Elevated Mortality Risk in the First Year Post-Diagnosis of Sarcoidosis: A Comprehensive Population-Based Cohort Study.

Patt Y, Sharif K, David P, Hen O, Gendelman O, Elizur Y Medicina (Kaunas). 2024; 60(11).

PMID: 39596972 PMC: 11596794. DOI: 10.3390/medicina60111787.

Electrocardiographic abnormalities attributable to infiltrative cardiomyopathies: review and prevalence in patients with congestive heart failure.

Mustafa M, White C, Harris E, Tawfellos G, Oredegbe A, Torosoff M Clin Res Cardiol. 2024; .

PMID: 39466445 DOI: 10.1007/s00392-024-02568-2.

References

Rajoriya N, Wotton C, Yeates D, Travis S, Goldacre M . Immune-mediated and chronic inflammatory disease in people with sarcoidosis: disease associations in a large UK database. Postgrad Med J. 2009; 85(1003):233-7. DOI: 10.1136/pgmj.2008.067769. View

Nardi A, Brillet P, Letoumelin P, Girard F, Brauner M, Uzunhan Y . Stage IV sarcoidosis: comparison of survival with the general population and causes of death. Eur Respir J. 2011; 38(6):1368-73. DOI: 10.1183/09031936.00187410. View

Shorr A, Helman D, Davies D, Nathan S . Sarcoidosis, race, and short-term outcomes following lung transplantation. Chest. 2004; 125(3):990-6. DOI: 10.1378/chest.125.3.990. View

Rabin D, Thompson B, Brown K, Judson M, Huang X, Lackland D . Sarcoidosis: social predictors of severity at presentation. Eur Respir J. 2004; 24(4):601-8. DOI: 10.1183/09031936.04.00070503. View

Shorr A, Davies D, Nathan S . Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest. 2003; 124(3):922-8. View

Reich J . Concurrent sarcoidosis and lung cancer. Chest. 2009; 136(3):943. DOI: 10.1378/chest.09-0711. View

Heijckmann A, Drent M, Dumitrescu B, de Vries J, Nieuwenhuijzen Kruseman A, Wolffenbuttel B . Progressive vertebral deformities despite unchanged bone mineral density in patients with sarcoidosis: a 4-year follow-up study. Osteoporos Int. 2008; 19(6):839-47. PMC: 2358936. DOI: 10.1007/s00198-007-0513-y. View

Shorr A, Helman D, Davies D, Nathan S . Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J. 2005; 25(5):783-8. DOI: 10.1183/09031936.05.00083404. View

Vorselaars A, Snijder R, Grutters J . Increased number of pulmonary embolisms in sarcoidosis patients. Chest. 2012; 141(3):826-827. DOI: 10.1378/chest.11-2514. View

10.

Frediani B, Falsetti P, Bisogno S, Baldi F, Acciai C, Filippou G . Effects of high dose methylprednisolone pulse therapy on bone mass and biochemical markers of bone metabolism in patients with active rheumatoid arthritis: a 12-month randomized prospective controlled study. J Rheumatol. 2004; 31(6):1083-7. View

11.

Kron J, Sauer W, Schuller J, Bogun F, Crawford T, Sarsam S . Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis. Europace. 2012; 15(3):347-54. DOI: 10.1093/europace/eus316. View

12.

Jamilloux Y, Bonnefoy M, Valeyre D, Varron L, Broussolle C, Seve P . Elderly-onset sarcoidosis: prevalence, clinical course, and treatment. Drugs Aging. 2013; 30(12):969-78. DOI: 10.1007/s40266-013-0125-5. View

13.

Ohira H, Tsujino I, Ishimaru S, Oyama N, Takei T, Tsukamoto E . Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging. 2007; 35(5):933-41. DOI: 10.1007/s00259-007-0650-8. View

14.

Christie J, Edwards L, Kucheryavaya A, Aurora P, Dobbels F, Kirk R . The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report--2010. J Heart Lung Transplant. 2010; 29(10):1104-18. DOI: 10.1016/j.healun.2010.08.004. View

15.

Ji J, Shu X, Li X, Sundquist K, Sundquist J, Hemminki K . Cancer risk in hospitalized sarcoidosis patients: a follow-up study in Sweden. Ann Oncol. 2009; 20(6):1121-6. DOI: 10.1093/annonc/mdn767. View

16.

Mehta D, Mori N, Goldbarg S, Lubitz S, Wisnivesky J, Teirstein A . Primary prevention of sudden cardiac death in silent cardiac sarcoidosis: role of programmed ventricular stimulation. Circ Arrhythm Electrophysiol. 2011; 4(1):43-8. DOI: 10.1161/CIRCEP.110.958322. View

17.

Bourbonnais J, Samavati L . Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J. 2008; 32(2):296-302. DOI: 10.1183/09031936.00175907. View

18.

Varron L, Cottin V, Schott A, Broussolle C, Seve P . Late-onset sarcoidosis: a comparative study. Medicine (Baltimore). 2012; 91(3):137-143. DOI: 10.1097/MD.0b013e3182569f91. View

19.

Marcellis R, Lenssen A, de Vries G, Baughman R, van der Grinten C, Verschakelen J . Is there an added value of cardiopulmonary exercise testing in sarcoidosis patients?. Lung. 2012; 191(1):43-52. DOI: 10.1007/s00408-012-9432-6. View

20.

Wille K, Gaggar A, Hajari A, Leon K, Barney J, Smith K . Bronchiolitis obliterans syndrome and survival following lung transplantation for patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2009; 25(2):117-24. View